Cirrhotic cardiomyopathy (CCM) is defined as systolic or diastolic dysfunction in the absence
of prior heart disease or another identifiable cause in patients with cirrhosis, in whom it is an …

Transjugular intrahepatic portosystemic shunt (TIPS) is an effective interventional procedure
to relieve portal hypertension, which is a main mechanism for the development of …

Background Atrial fibrillation (AF) is the most common arrhythmia and its management in
cirrhosis can be challenging due to the altered hepatic metabolism of medications and …

Abstract Approximately 30% to 70% of patients with cirrhosis have QT interval prolongation.
In patients without cirrhosis, QT prolongation is associated with an increased risk of …

Cardiac dysfunction associated with cirrhosis in the absence of preexisting heart disease is
a condition known as cirrhotic cardiomyopathy (CCM). Cardiac abnormalities consist of …

Liver diseases affect the heart and the vascular system. Cardiovascular complications
appear to be a leading cause of death in patients with non-alcoholic fatty liver disease …

Abnormal cardiac function in the setting of cirrhosis and in the absence of a primary cardiac
disease is known as cirrhotic cardiomyopathy. The pathogenesis of cirrhotic cardiomyopathy …

The curative therapy for patients with end-stage liver disease is liver transplantation.
However, liver transplantation challenges the cardiovascular system, and is associated with …

Background Prevention of ischemic stroke is an essential part of managing atrial fibrillation
(AF). In recent years, direct oral anticoagulants (DOACs) have emerged as an alternative to …

In patients with cirrhosis, cardiac dysfunction in the absence of preexisting heart disease is a
condition known as cirrhotic cardiomyopathy (CCM).(1, 2) It is now clear that CCM plays an …